Tumor cells use a certain type of immune cells, the so-called neutrophils, to enhance their ability to form metastases. Scientists have deciphered the mechanisms of this collaboration and found strategies for blocking them. This is reported by researchers from the University of Basel and the University Hospital of Basel in the scientific journal Nature.
A better understanding of the features that define the interplay between cancer cells and immune cells is key to identifying new cancer therapies. Yet, focus is often given to those interactions that occur within the primary tumor and its microenvironment, while the role of immune cells during cancer dissemination in patients remains largely uncharacterized.
For example, certain immune cells, the so-called neutrophils, often enter into an alliance with tumor cells that contributes significantly to the development of metastases. This was found by Prof. Nicola Aceto's interdisciplinary research team at the Department of Biomedicine of the University of Basel and the University Hospital of Basel.
Neutrophils escort circulating tumor cells
Circulating tumor cells (CTCs) are cancer cells that leave a primary tumor and enter the bloodstream, on their way to distant organs. These CTCs are regarded as precursors of metastases. They can be found in the blood of patients as single cells, cell clusters or in groups with neutrophils. The researchers discovered that CTCs in close contact to neutrophils proliferate much more than other circulating cancer cells.
"Surprising is that the patient's own neutrophils act by protecting CTCs in circulation, allowing CTCs to more efficiently seed metastasis", states Prof. Aceto. Indeed, the presence of CTC-neutrophil clusters in the bloodstream also correlates with a poor prognosis of breast cancer patients.
Blocking the alliance between tumor cells and neutrophils
"We undertook a number of experiments to fully characterize CTC-neutrophil clusters from patients and mouse models, aiming to find strategies to suppress their ability to form metastasis," says Prof. Aceto, holder of an ERC starting grant and SNSF professorship. To this end, the researchers combined state-of-the-art single cell sequencing techniques, microfluidic technologies and genetic knockout experiments to gain insights into the biology of CTC-neutrophil clusters. They found that the neutrophils enhance the metastasis-seeding ability of CTCs by releasing specific messenger substances, such as cytokines. When in turn this release of cytokines was blocked, the pro-metastatic effects of neutrophils were abrogated.
Altogether, the researchers were able not only to uncover the role of CTC-neutrophil clusters, but also to identify their vulnerabilities. These results may lead to the development of new anti-metastatic drugs.